Company Active LTD

Company profile

Shift Bioscience Limited

Shift Bioscience

Shift Bioscience Limited is a UK company with status active founded in 2017 based in East of England.

CRN
10793871
Founded
2017
Age
9

Overview

Legal name
SHIFT BIOSCIENCE LIMITED
Region
East of England
Registered address
SALISBURY HOUSE
STATION ROAD
CAMBRIDGE
UNITED KINGDOM
CB1 2LA
Insolvency history
No

Latest accounts

Financial period: 1 Jul 2024 to 30 Jun 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
18

Company events

Reference milestones and recent Companies House filing stream events.

8 events
27 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

27 May
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUYxTjRFWExhZGlxemtjeA | Paper/PDF filed

Published 27 May 2026 23:00

13 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

11 Apr
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUVZT0RTUkxhZGlxemtjeA | Paper/PDF filed

Published 11 Apr 2026 22:45

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

01 Nov
2024

Mortgage Create With Deed With Charge Number Charge Creation Date

Mortgage

MR01 | Transaction MzQ0MTc3NTUwN2FkaXF6a2N4

Published 06 Nov 2024 11:02

30 May
2017

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2023
Funded years
2023, 2025
Age at first award
6 years

Projects

2025 Collaborative R&D Lead participant

In vivo validation of safe and effective gene targets for cellular reprogramming therapies

1 Apr 2025 to 30 Sep 2026

Awarded
£347,693
Total cost £496,704

Although UK life expectancies have increased, healthy life expectancies have not increased at the same rate. Consequently, although we are living longer, we are spending more time in poor health. Men and women born in England in 2018-2020 can expect to live to 79.4 and 83.1 years, respectively, but will spend the last 16.3 and 19.3 years, respectively, in...

2023 Collaborative R&D Lead participant

Discovery of safe and effective gene targets for cellular reprogramming therapies

1 Jul 2023 to 31 Dec 2024

Awarded
£349,993
Total cost £499,990

We are living longer, but not necessarily enjoying good health in later life. Men and women born in England in 2018-2020 can expect to live to 79.4 and 83.1 years, respectively, but will spend the last 16.3 and 19.3 years, respectively, in 'not good' health. The ageing population is already placing huge pressures on the overstretched NHS and social care s...

Product types

Collaborative R&D